Trial Profile
A Safety, Tolerability, Pharmacokinetic, and Efficacy Study of ABY-035/AFO2 Given as Multiple Doses in Sequential Escalating Dose Cohorts in Psoriasis Subjects
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 24 Apr 2019
Price :
$35
*
At a glance
- Drugs ABY 035 (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; First in man
- Sponsors Affibody
- 17 Apr 2019 Planned End Date changed from 1 Dec 2019 to 1 Mar 2020.
- 17 Apr 2019 Planned primary completion date changed from 1 Dec 2019 to 1 Feb 2020.
- 17 Apr 2019 Planned initiation date changed from 1 Apr 2019 to 1 Oct 2019.